Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Harmony Biosciences Holdings Inc (NQ: HRMY )

29.95 +0.60 (+2.04%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 233,847
Open 29.59
Bid (Size) 28.99 (1)
Ask (Size) 30.84 (1)
Prev. Close 29.35
Today's Range 29.05 - 30.11
52wk Range 18.61 - 39.27
Shares Outstanding 56,791,861
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Harmony Biosciences (HRMY) Q1 2024 Earnings Call Transcript
HRMY earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial

Performance

YTD
-2.73%
-2.73%
1 Month
+2.46%
+2.46%
3 Month
-7.85%
-7.85%
6 Month
+3.17%
+3.17%
1 Year
-16.78%
-16.78%

More News

Read More
HRMY Stock Earnings: Harmony Biosciences Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Harmony Biosciences Expands It CNS-Focused Pipeline With Epilepsy Candidate, Q1 Earnings Beat Street View
Via Benzinga
Topics Earnings
Exposures Financial
Key Takeaways From Harmony Biosciences Analyst Ratings
Via Benzinga
Evaluating Harmony Biosciences: Insights From 8 Financial Analysts
Via Benzinga
Analyst Ratings For Harmony Biosciences
Via Benzinga
NASDAQ:HRMY stands out as a growth opportunity that won't break the bank.
Via Chartmill
Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy
From Harmony Biosciences
Via GlobeNewswire
Updates: HRMY, MELI, SWAV
Via Talk Markets
Harmony Biosciences (HRMY) Q4 2023 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
From Harmony Biosciences
Via GlobeNewswire
A Glimpse Into The Expert Outlook On Harmony Biosciences Through 6 Analysts
Via Benzinga
The 3 Most Undervalued Small-Cap Stocks to Buy in February 2024
Via InvestorPlace
The 3 Most Undervalued Russell 2000 Stocks to Buy in February 2024
Via InvestorPlace
NASDAQ:HRMY: good value for what you're paying.
Via Chartmill
Investors should take notice of NASDAQ:HRMY—it offers a great deal for the fundamentals it presents.
Via Chartmill
Why Harmony Biosciences Stock Got Slammed Today
Via The Motley Fool
2023 Year In Review
Via Talk Markets
Topics Stocks
Exposures US Equities
NASDAQ:HRMY is showing good growth, while it is not too expensive.
Via Chartmill
7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar
Via InvestorPlace
NASDAQ:HRMY, an undervalued stock with good fundamentals.
Via Chartmill
Russell 2000 Front-Runners: 3 Stocks to Keep an Eye On
Via InvestorPlace
Looking for growth without the hefty price tag? Consider NASDAQ:HRMY.
Via Chartmill
NASDAQ:HRMY is probably undervalued for the fundamentals it is displaying.
Via Chartmill
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.